Notice of Results

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2019 on 11 October 2019

Oxford, UK, and Cambridge, MA, US, 10 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, will announce its financial results for the second quarter and half year ended 31 July 2019 on 11 October 2019.

Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the second quarter and half year results press release, and a replay of the call will also be available through the Company’s website, www.summitplc.com.

About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit
Glyn Edwards / Richard Pye (UK office)	Tel:	44 (0)1235 443 951
Michelle Avery (US office)		[phone]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel:	[phone]
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker)	Tel:	[phone]
Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint Broker)	Tel:	[phone]
Phil Walker / Dominic Wilson
MSL Group (US)	Tel:	[phone]
Erin Anthoine		[e-mail]
Consilium Strategic Communications (UK)	Tel:	[phone]
Mary-Jane Elliott / Sue Stuart / Sukaina Virji		[e-mail]
Lindsey Neville

-END-